Skip to main content
. Author manuscript; available in PMC: 2023 Sep 28.
Published in final edited form as: JACC Heart Fail. 2022 Mar 9;10(4):266–275. doi: 10.1016/j.jchf.2021.12.004

Figure 3: (A) Proportion of patients on ≥50% target dose of ACEi/ARBs; (B) proportion of patients on ≥50% target dose of beta-blockers.

Figure 3:

Non-frail participants (FI Class I) were significantly more likely to be uptitrated to achieve higher doses of evidence-based therapies as compared with those with high frailty burden (FI Class III)